Janusz Rolski

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Purvish Mahendra Parikh, Joachim von Pawel, Bonne Biesma et autres

PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS This noninferiority, phase III, randomized study compared …

de (code pays fourni par la source)

First-Line Treatment of Advanced/Metastatic Melanoma with Anti-PD-1 Antibodies: Multicenter Experience in Poland

Bożena Cybulska-Stopa, Renata Pacholczak‐Madej, Grażyna Kamińska‐Winciorek, Marcin Ziętek et autres

Aim: To evaluate treatment results in advanced/metastatic melanoma patients treated with anti-PD-1 immunotherapy in routine practice in oncology centers in Poland. Methods: Multicenter retrospective analysis included 499 patients with unresectable/metastatic (stage IIIC–IV) melanoma treated with anti-PD-1 in first-line therapy. Results: Estimated median …

pl (code pays fourni par la source)

1117P Immunotherapy in octogenarian and nonagenarian metastatic melanoma patients

Bożena Cybulska-Stopa, Marcin Ziętek, A.M.M. Czarnecka, Karolina Piejko et autres

pl (code pays fourni par la source)

Immunotherapy or targeted therapy as first-line treatment of patients with advanced/metastatic melanoma with the BRAF mutation — a single-center analysis

Bożena Cybulska-Stopa, Karolina Piejko, Renata Pacholczak‐Madej, Małgorzata Domagała-Haduch et autres

Introduction. One of the most important achievements of contemporary oncology is the discovery of new therapeutic possibilities: targeted therapy and immunotherapy associated with checkpoint inhibitors. It has not been unequivocally determined so far which therapy should be used as first-line treatment in …

pl (code pays fourni par la source)

Immunoterapia czy terapia celowana w pierwszej linii leczenia chorych na zaawansowane/rozsiane czerniaki z obecnością mutacji BRAF — analiza jednoośrodkowa

Bożena Cybulska-Stopa, Karolina Piejko, Renata Pacholczak‐Madej, Małgorzata Domagała-Haduch et autres

Wstep. Jednym z najwazniejszych osiągniec wspolczesnej onkologii jest odkrycie nowych mozliwości terapeutycznych: terapii celowanej oraz immunoterapii związanej z inhibitorami punktow kontrolnych. Dotychczas nie ustalono jednoznacznie, ktora terapia powinna byc zastosowana jako leczenie pierwszej linii u chorych na zaawansowane/rozsiane czerniaki z obecnością mutacji …

Real-world treatment practice in patients with advanced melanoma

Bożena Cybulska-Stopa, Karolina Piejko, Renata Pacholczak‐Madej, Małgorzata Domagała-Haduch et autres

INTRODUCTION: The treatment outcomes of patients with advanced/metastatic melanoma were poor before the use of new therapeutic options. MATERIAL AND METHODS: A retrospective analysis was conducted among 287 patients with unresectable stage III and stage IV melanoma treated at the Maria Sklodowska-Curie …

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

John Robert Mackey, Miguel Martín, Tadeusz Pieńkowski, Janusz Rolski et autres

ca, es, pl, fr, us, hu, gb, se, br (code pays fourni par la source)

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study

John F.R. Robertson, Justin P.O. Lindemann, Antonio Llombart‐Cussac, Janusz Rolski et autres

gb, es, pl, us (code pays fourni par la source)

Diagnostic, predictive and prognostic verification of DNA flow cytometric measurements performed at diagnosis for non-Hodgkin's lymphoma adult patients.

Bożena Lackowska, Andrzej Gruchała, Agnieszka Jaszcz-Gruchała, Janusz Rolski et autres

More than ten years ago we made first attempts at valuating a prognostic power of flow cytometric DNA measurement results for patients with non-Hodgkin's lymphoma. In multivariate overall survival analysis, S-phase fraction (SPF) showed to be the only independent prognostic factor within …

The possibility of lapatinib treatment for breast cancer patients with central nervous system metastases. Case study and literature review

Janusz Rolski, Bożenna Karczmarek-Borowska, Anetta Śmietana

In patients with breast cancer with overexpression of the HER2 receptor, during treatment with trastuzumab, in 30% of cases brain metastases are observed. The use of lapatinib with capecitabine (L + C) seems to be an efficacious method of curing patients in …

pl (code pays fourni par la source)

Response to subsequent endocrine therapy in patients treated with fulvestrant 500mg or anastrozole: results from FIRST

John F.R. Robertson, Justin P.O. Lindemann, Sally Garnett, Antonio Llombart‐Cussac et autres

Background: The Fulvestrant fIRst-line Study comparing endocrine Treatments (FIRST) compared fulvestrant 500mg with anastrozole as first-line endocrine therapy in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer. Fulvestrant 500mg was at least as effective as anastrozole in terms of clinical benefit …

gb, es, pl, us (code pays fourni par la source)

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

Miguel Martín, Henri Hubert Roche, Tamás Pintér, John P. Crown et autres

es, fr, hu, ie, ca, de, pl, au, in, us, gb (code pays fourni par la source)